Evidence map›Paper›PMID 37059218›Full record

ArticleNeuroscience letters2023

The D3 receptor antagonist SR 21502 reduces cue-induced reinstatement of methamphetamine-seeking in rats.

Robert Ranaldi, Patrick Timken, Daleya Parasram, Tasmia Ali, Sixue Zhang, Omar Moukha-Chafiq, Corinne Augelli-Szafran, John M Streicher

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuroscience letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Robert RanaldiDepartment of Psychology, Queens College, The City University of New York, Flushing, NY, USA. Electronic address: robert.ranaldi@qc.cuny.edu.
Patrick TimkenDepartment of Psychology, Queens College, The City University of New York, Flushing, NY, USA.
Daleya ParasramDepartment of Psychology, Queens College, The City University of New York, Flushing, NY, USA.
Tasmia AliDepartment of Psychology, Queens College, The City University of New York, Flushing, NY, USA.
Sixue ZhangScientific Platforms, Southern Research Institute, Birmingham, AL, USA.
Omar Moukha-ChafiqScientific Platforms, Southern Research Institute, Birmingham, AL, USA.
Corinne Augelli-SzafranScientific Platforms, Southern Research Institute, Birmingham, AL, USA.
John M StreicherDepartment of Pharmacology, College of Medicine and the Comprehensive Pain and Addiction Center, University of Arizona, Tucson, AZ, USA.
Queens College, CUNY · USSouthern Research Institute · USUniversity of Arizona · US

Funding

Environmental Enrichment as a Treatment for Heroin Use DisorderSC3GM130430 · NIGMS · QUEENS COLLEGE · PI RANALDI, ROBERT · 2019 to 2022
$462k
NIGMS NIH HHS SC3 GM130430
6 · The paper itself

Abstract

There is as of yet no FDA-approved medication for methamphetamine use disorder. Although dopamine D3 receptor antagonists have been shown to be useful in reducing methamphetamine seeking in animal models their translation to the clinic has been hindered because currently tested compounds can produce dangerously high blood pressure. Thus, it is important to continue to explore other classes of D3 antagonists. We report here the effects of SR 21502, a selective D3 receptor antagonist, on cue-induced reinstatement (i.e., relapse) of methamphetamine-seeking in rats. In Experiment 1, rats were trained to self-administer methamphetamine under a fixed ratio schedule of reinforcement followed by extinction of the response. Then, animals were tested with one of several doses of SR 21502 on cue-induced reinstatement of responding. SR 21502 significantly reduced cue-induced reinstatement of methamphetamine-seeking. In Experiment 2, animals were trained to lever press for food under a PR schedule and tested with the lowest dose of SR 21502 that caused a significant reduction in Experiment 1. These animals responded on average 8 times more than the vehicle-treated rats in Experiment 1, eliminating the possibility that SR 21502-treated rats in Experiment 1 responded less because they were incapacitated. In summary, these data suggest that SR 21502 may selectively inhibit methamphetamine-seeking and may constitute a promising pharmacotherapeutic agent for methamphetamine or other drug use disorders.

Indexed as

MethamphetamineAnimalsCuesDopamine AntagonistsDose-Response Relationship, DrugExtinction, PsychologicalImidazolesPyridinesRatsReinforcement, PsychologySelf AdministrationDopamine AntagonistsImidazolesMethamphetaminePyridinesSR 21502Dopamine receptorsPsychostimulantsRelapseSubstance use disorderTreatment

Identifiers

PMID37059218
PMCPMC10189795
OpenAlexW4365143715

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.